MA39193A1 - Modulateurs du gpr6 à base de tétrahydropyridopyrazines - Google Patents

Modulateurs du gpr6 à base de tétrahydropyridopyrazines

Info

Publication number
MA39193A1
MA39193A1 MA39193A MA39193A MA39193A1 MA 39193 A1 MA39193 A1 MA 39193A1 MA 39193 A MA39193 A MA 39193A MA 39193 A MA39193 A MA 39193A MA 39193 A1 MA39193 A1 MA 39193A1
Authority
MA
Morocco
Prior art keywords
tetrahydropyridopyrazines
gpr6
modulators based
gpr6 modulators
compounds
Prior art date
Application number
MA39193A
Other languages
English (en)
Other versions
MA39193B1 (fr
Inventor
Stephen Hitchcock
Holger Monenschein
Holly Reichard
Shota Kikuchi
Todd Macklin
Maria Hopkins
Jason Brown
Kristin Schleicher
Hukai Sun
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52440811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39193(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA39193A1 publication Critical patent/MA39193A1/fr
Publication of MA39193B1 publication Critical patent/MA39193B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés de formule (i) : qui sont utiles comme modulateurs du gpr6, des compositions pharmaceutiques les contenant, des procédés de traitement de maladies associées au gpr6, et des procédé de fabrication des composés et de leurs intermédiaires.
MA39193A 2013-12-20 2014-12-19 Modulateurs du gpr6 à base de tétrahydropyridopyrazines MA39193B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361919661P 2013-12-20 2013-12-20
PCT/US2014/071543 WO2015095728A1 (fr) 2013-12-20 2014-12-19 Modulateurs du gpr6 à base de tétrahydropyridopyrazines

Publications (2)

Publication Number Publication Date
MA39193A1 true MA39193A1 (fr) 2017-06-30
MA39193B1 MA39193B1 (fr) 2018-04-30

Family

ID=52440811

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39193A MA39193B1 (fr) 2013-12-20 2014-12-19 Modulateurs du gpr6 à base de tétrahydropyridopyrazines

Country Status (42)

Country Link
US (4) US9181249B2 (fr)
EP (2) EP3453709A1 (fr)
JP (1) JP6538697B2 (fr)
KR (1) KR102441531B1 (fr)
CN (2) CN105829309B (fr)
AR (2) AR098872A1 (fr)
AU (1) AU2014368992C1 (fr)
BR (1) BR112016014020B1 (fr)
CA (1) CA2934247C (fr)
CL (1) CL2016001595A1 (fr)
CR (1) CR20160321A (fr)
CY (1) CY1121395T1 (fr)
DK (1) DK3083620T3 (fr)
DO (1) DOP2016000144A (fr)
EA (1) EA032443B1 (fr)
EC (1) ECSP16061758A (fr)
ES (1) ES2702187T3 (fr)
GE (1) GEP201706783B (fr)
HR (1) HRP20182004T1 (fr)
HU (1) HUE042443T2 (fr)
IL (1) IL246177B (fr)
JO (1) JO3466B1 (fr)
LT (1) LT3083620T (fr)
MA (1) MA39193B1 (fr)
MX (1) MX2016008188A (fr)
MY (1) MY177031A (fr)
NZ (1) NZ721723A (fr)
PE (1) PE20160751A1 (fr)
PH (1) PH12016501192B1 (fr)
PL (1) PL3083620T4 (fr)
PT (1) PT3083620T (fr)
RS (1) RS58092B1 (fr)
SG (1) SG11201604921TA (fr)
SI (1) SI3083620T1 (fr)
SM (1) SMT201800668T1 (fr)
TN (1) TN2016000244A1 (fr)
TR (1) TR201900038T4 (fr)
TW (2) TWI809395B (fr)
UA (1) UA120427C2 (fr)
UY (1) UY35908A (fr)
WO (1) WO2015095728A1 (fr)
ZA (1) ZA201604703B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014015197A8 (pt) 2011-12-21 2017-06-13 Novira Therapeutics Inc agentes antivirais de hepatite b
EP2882722B1 (fr) 2012-08-13 2016-07-27 Takeda Pharmaceutical Company Limited Dérivés de quinoxaline en tant que modulateurs du gpr6
KR102271574B1 (ko) 2012-08-28 2021-07-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
WO2014131847A1 (fr) 2013-02-28 2014-09-04 Janssen R&D Ireland Sulfamoyl-arylamides et leur utilisation en tant que médicaments pour le traitement de l'hépatite b
MX353412B (es) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
DK2997019T3 (en) 2013-05-17 2018-12-03 Janssen Sciences Ireland Uc SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
TWI733288B (zh) 2013-05-17 2021-07-11 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
HRP20180791T1 (hr) 2013-07-25 2018-09-07 Janssen Sciences Ireland Uc Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
CA2923712C (fr) 2013-10-23 2021-11-02 Janssen Sciences Ireland Uc Derives de carboxamide et leur utilisation en tant que medicaments pour le traitement de l'hepatite b
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
CA2936947A1 (fr) 2014-02-05 2015-08-13 Novira Therapeutics, Inc. Polytherapie pour le traitement d'infections par le vhb
TW201620893A (zh) 2014-02-06 2016-06-16 健生科學愛爾蘭無限公司 磺醯胺基吡咯醯胺衍生物及其用作治療ｂ型肝炎之醫藥品的用途
WO2015123505A1 (fr) * 2014-02-14 2015-08-20 Takeda Pharmaceutical Company Limited Modulateurs pyridopyrazines de gpr6
JP2018510159A (ja) 2015-03-19 2018-04-12 ノヴィラ・セラピューティクス・インコーポレイテッド アゾカン及びアゾナン誘導体及びｂ型肝炎感染症の治療法
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
TW201718496A (zh) 2015-09-29 2017-06-01 諾維拉治療公司 B型肝炎抗病毒劑之晶型
AU2017248828A1 (en) 2016-04-15 2018-11-01 Janssen Sciences Ireland Uc Combinations and methods comprising a capsid assembly inhibitor
JOP20180057A1 (ar) * 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
MX2020009531A (es) 2018-03-14 2020-10-05 Janssen Sciences Ireland Unlimited Co Regimen posologico del modulador del ensamblaje de la capside.
WO2020169784A1 (fr) 2019-02-22 2020-08-27 Janssen Sciences Ireland Unlimited Company Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
AR119732A1 (es) 2019-05-06 2022-01-05 Janssen Sciences Ireland Unlimited Co Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb
WO2026067262A1 (fr) * 2024-09-26 2026-04-02 四川科伦药物研究院有限公司 Composé à cycles fusionnés, composition pharmaceutique le comprenant, utilisation et procédé

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4426296A (en) * 1994-08-11 1996-03-07 Takeda Chemical Industries Ltd. G protein coupled receptor protein, production, and use thereof
CN1364167A (zh) * 1999-02-26 2002-08-14 阿瑞那制药公司 G蛋白偶联受体6的小分子调节剂
US20030229113A1 (en) 2000-03-24 2003-12-11 Koji Hashimoto Keratinocyte growth inhibitors and hydroxamic acid derivatives
WO2004038416A1 (fr) * 2002-10-24 2004-05-06 Bayer Healthcare Ag Diagnostic et therapeutique de maladies associees au recepteur 6 couple a la proteine g humain (gpr6)
CA2513684A1 (fr) 2003-01-31 2004-08-19 Merck & Co., Inc. Derives d'acide 3-amino-4-phenylbutanoique utilises comme inhibiteurs de dipeptidyle peptidase pour le traitement ou la prevention du diabete
SE0400285D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
AU2007242555B2 (en) * 2006-04-21 2010-12-16 Pfizer Products Inc. Pyridine[3,4-b]pyrazinones
CA2651072A1 (fr) 2006-05-01 2007-11-08 Pfizer Products Inc. Composes heterocycliques 2-amino-substitues a cycles fusionnes
CA2688471C (fr) 2007-06-05 2017-01-17 Astrium Limited Systeme et procede de test a distance
GB0710844D0 (en) 2007-06-06 2007-07-18 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
GB2449929A (en) 2007-06-08 2008-12-10 Snell & Wilcox Ltd Hierarchical spatial resolution building processes to fill holes in an interpolated image
SI2440547T1 (sl) 2009-06-12 2023-05-31 Abivax Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju
WO2013087815A1 (fr) 2011-12-15 2013-06-20 Merz Pharma Gmbh & Co. Kgaa Composition pharmaceutique liquide contenant un dérivé de pyrazolopyrimidine et utilisations pharmaceutiques de celle-ci
WO2013087808A1 (fr) 2011-12-15 2013-06-20 Merz Pharma Gmbh & Co. Kgaa Composition pharmaceutique comprenant une pyrazolopyrimidine et une cyclodextrine
JP6345651B2 (ja) 2012-05-09 2018-06-20 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ヘテロアリール化合物及びその使用方法
EP2882722B1 (fr) * 2012-08-13 2016-07-27 Takeda Pharmaceutical Company Limited Dérivés de quinoxaline en tant que modulateurs du gpr6
FR2995937B1 (fr) 2012-09-21 2014-09-26 Exoes Ensemble de production d'electricite a moteur a pression de vapeur
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6

Also Published As

Publication number Publication date
SG11201604921TA (en) 2016-07-28
LT3083620T (lt) 2019-02-11
NZ721723A (en) 2021-07-30
UY35908A (es) 2015-07-31
CA2934247A1 (fr) 2015-06-25
PH12016501192A1 (en) 2016-08-15
ES2702187T3 (es) 2019-02-27
IL246177B (en) 2019-11-28
RS58092B1 (sr) 2019-02-28
TWI730937B (zh) 2021-06-21
CL2016001595A1 (es) 2017-01-13
JO3466B1 (ar) 2020-07-05
TWI809395B (zh) 2023-07-21
US10077266B2 (en) 2018-09-18
ECSP16061758A (es) 2018-02-28
EA201691272A1 (ru) 2017-05-31
JP6538697B2 (ja) 2019-07-03
BR112016014020B1 (pt) 2023-02-28
US20180346464A1 (en) 2018-12-06
BR112016014020A8 (pt) 2018-01-30
US9708313B2 (en) 2017-07-18
TN2016000244A1 (en) 2017-10-06
EP3453709A1 (fr) 2019-03-13
TR201900038T4 (tr) 2019-01-21
HRP20182004T1 (hr) 2019-02-08
TW201605854A (zh) 2016-02-16
PL3083620T3 (pl) 2019-09-30
MX2016008188A (es) 2016-09-29
PL3083620T4 (pl) 2019-09-30
CN105829309A (zh) 2016-08-03
US20160031881A1 (en) 2016-02-04
CY1121395T1 (el) 2020-05-29
UA120427C2 (uk) 2019-12-10
DK3083620T3 (en) 2019-01-14
ZA201604703B (en) 2018-11-28
US10738046B2 (en) 2020-08-11
US20170283414A1 (en) 2017-10-05
PE20160751A1 (es) 2016-08-01
EA032443B1 (ru) 2019-05-31
IL246177A0 (en) 2016-08-02
SMT201800668T1 (it) 2019-01-11
PT3083620T (pt) 2019-01-17
GEP201706783B (en) 2017-11-27
TW202202497A (zh) 2022-01-16
BR112016014020A2 (pt) 2017-08-08
JP2017502027A (ja) 2017-01-19
AR098872A1 (es) 2016-06-22
KR102441531B1 (ko) 2022-09-07
SI3083620T1 (sl) 2019-02-28
US9181249B2 (en) 2015-11-10
CN108658978A (zh) 2018-10-16
CR20160321A (es) 2016-09-28
EP3083620A1 (fr) 2016-10-26
EP3083620B1 (fr) 2018-10-03
AR129635A2 (es) 2024-09-11
PH12016501192B1 (en) 2016-08-15
MY177031A (en) 2020-09-02
AU2014368992B2 (en) 2018-09-13
DOP2016000144A (es) 2016-08-15
KR20160099705A (ko) 2016-08-22
AU2014368992C1 (en) 2019-02-21
MA39193B1 (fr) 2018-04-30
CA2934247C (fr) 2023-01-17
HUE042443T2 (hu) 2019-06-28
WO2015095728A1 (fr) 2015-06-25
CN105829309B (zh) 2018-05-15
AU2014368992A1 (en) 2016-07-07
US20150175602A1 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
MA39193B1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
MA35920B1 (fr) Composés destinés au traitement de l'amyotrophie spinale
MA42109A (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
MX388682B (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
MA37959A2 (fr) Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
EA201500926A1 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX353706B (es) Anticuerpos contra csf-1r humano y usos de los mismos.
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
EA201790070A1 (ru) Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70
EA201500403A1 (ru) Соединения, активирующие теломеразу, и способы их применения
MX2018007075A (es) Compuestos policiclicos como inhibidores de tirosina quinasa de bruton.
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
EA201691141A1 (ru) Соединения против ccr6
PH12019501362A1 (en) Polymorphs
BR112014013138A2 (pt) anilinas substituídas como antagonistas de ccr(4)
EA201890898A1 (ru) Новые соединения и конъюгаты криптофицина, их получение и их терапевтическое применение
EA201790570A1 (ru) Модуляторы р2х7
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
PH12020550947A1 (en) Polymorphs
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA39337A1 (fr) Modulateurs de pyrazines de gpr6